ACUTE MYELOID LEUKEMIA

This early-phase trial is testing whether adding the drug emapalumab to standard medications can safely prevent graft-versus-host disease (GVHD) in 15 adults with leukemia or myelodysplastic syndrome receiving a reduced-intensity stem cell transplant. Emapalumab blocks a protein …

This study tests a new way to prepare donor stem cells (called Orca-Q) for people with blood cancers like leukemia or MDS who need a transplant. The goal is to see if this engineered graft is safe and helps the body accept the new cells with fewer complications. About 300 partici…

This Phase 3 trial tests whether adding the drug venetoclax to standard chemotherapy helps adults with newly diagnosed acute myeloid leukemia (AML) or a related high-risk condition. About 650 participants aged 18 to 75 will receive either venetoclax or a placebo alongside chemo. …

This phase I trial tests whether adding the experimental drug iadademstat to two standard leukemia medications (azacitidine and venetoclax) is safe and tolerable for adults with newly diagnosed acute myeloid leukemia (AML) who cannot undergo intensive chemotherapy. Iadademstat bl…

This phase 2 trial tests whether adding vedolizumab to standard drugs (cyclophosphamide and tacrolimus) can prevent graft-versus-host disease (GVHD) in people receiving stem cell transplants for blood cancers like leukemia and myelodysplastic syndrome. GVHD occurs when donor immu…

This study is for adults with a certain type of acute myeloid leukemia (AML) who are in remission and planning a stem cell transplant. It compares a combination of two drugs, venetoclax and azacitidine, against standard high-dose chemotherapy as a 'consolidation' step before the …

This phase II trial tests several experimental drug combinations against the standard treatment for high-risk acute myeloid leukemia (AML) in patients aged 59 or younger. The goal is to see if newer regimens, including venetoclax and liposome formulations, can better shrink cance…

This early-phase trial tests a drug called DR-18 in 40 adults with acute myeloid leukemia or myelodysplastic syndrome whose cancer returned or persisted after a stem cell transplant. DR-18 is a modified immune protein designed to boost the body's natural defenses against cancer c…

This study tests a new type of immunotherapy called CAR-T cells that are designed to recognize and attack cancer cells carrying a protein called CD7. It includes people with several blood cancers, such as T-cell acute lymphoblastic leukemia and acute myeloid leukemia. The goal is…

This early-phase trial is testing a new drug called HC-7366 in 18 adults with acute myeloid leukemia (AML) that has come back or not responded to other treatments. The main goal is to find a safe dose and check for side effects. Researchers hope this drug may offer a new option f…

This phase II trial is for older adults with a specific type of acute myeloid leukemia (AML) that has IDH gene mutations. Researchers want to find out whether starting treatment with an IDH-targeted drug (ivosidenib or enasidenib) followed by standard therapy (azacitidine plus ve…

This Phase 2 trial is testing a stem cell transplant from a donor for people with various blood cancers and bone marrow disorders. The transplant uses strong chemotherapy or radiation to wipe out the diseased marrow, then replaces it with healthy donor cells. A new combination of…

This early-phase trial tests a new type of cell therapy for people with relapsed or refractory acute myeloid leukemia (AML). The treatment uses a patient's own immune cells, engineered to recognize six different targets on leukemia cells. The study aims to see if this approach is…

This phase II trial tests whether adding gilteritinib to the usual two-drug therapy (azacitidine and venetoclax) can help older or frail adults with a specific type of acute myeloid leukemia (FLT3-mutated) achieve deeper remission. About 147 participants will be randomly assigned…

This early-stage trial tests a new type of immune cell therapy (called universal CAR T cells) for people with certain blood cancers, including T-cell leukemia and lymphoma. The therapy targets a protein called CD7 found on cancer cells. The study will check if the treatment is sa…

This early-phase trial is testing whether combining two oral drugs, eltanexor and venetoclax, is safe and effective for people with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) that has returned or not responded to prior treatment. The study will enroll 60 adult…

This early-phase trial tests a cell therapy called Orca-T combined with standard drugs to prevent graft-versus-host disease (GVHD) in 24 adults with advanced blood cancers (like leukemia or MDS) receiving stem cell transplants from partially matched donors. The main goal is to se…

This early-phase trial is testing a new type of CAR T-cell therapy, called CD4CAR, in people with acute myeloid leukemia (AML) that has come back or not responded to standard treatment. The therapy targets a protein called CD4 on leukemia cells. The goal is to safely eliminate as…

This study tests a new drug called CCS1477 (inobrodib) in people with advanced blood cancers like leukemia, lymphoma, and myeloma that have not responded to standard treatments. The drug is given as an oral capsule, either alone or combined with other cancer medicines. The goal i…

This study tests whether a combination of venetoclax and azacitidine works better than standard chemotherapy to keep high-risk acute myeloid leukemia (AML) from coming back before a stem cell transplant. About 216 adults who have already achieved remission after initial treatment…

This early-phase trial tests a combination of CAR T cells that target three different markers (CLL-1, CD33, and CD123) on leukemia cells in patients with relapsed or refractory acute myeloid leukemia. The study aims to see if this approach is safe and can shrink tumors. Only 10 p…

This phase 1 trial tests a new type of immunotherapy called universal CAR T cells in people with acute myeloid leukemia (AML) that has come back or not responded to treatment. The cells are engineered to recognize and attack leukemia cells by targeting four different proteins (CL…

This study tests a new experimental drug called EP0042 in adults with advanced acute myeloid leukemia (AML) or related blood cancers. The goal is to find a safe dose that might work against the cancer, either alone or with other treatments. About 70 participants will take part to…

This study follows patients who have already been taking ruxolitinib alone or with panobinostat in earlier trials and are still benefiting. Researchers will track side effects over time to see how safe these drugs are for long-term use. About 296 participants with conditions like…

This early-stage trial tests a new treatment called CD371-YSNVZ-IL18 CAR T cells for people with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. The main goal is to find the safest dose and see what side effects occur. About 15 participants w…

This study tests two different doses of the drug quizartinib as a maintenance therapy for adults with a specific type of acute myeloid leukemia (FLT3-ITD positive) who are in their first complete remission after initial treatment and have not had a stem cell transplant. The goal …

This study tests whether combining two drugs, revumenib and mezigdomide, is safe for people with specific types of acute leukemia that have returned or not responded to prior therapy. About 52 participants aged 12 and older will take part. The goal is to find the best dose and se…

This early-phase trial tests a drug called CRD3874-SI, which activates the STING pathway to boost the immune system's ability to fight cancer cells. It is for people with acute myeloid leukemia (AML) that has returned or not responded to previous treatments. The main goal is to f…

This study is testing a new approach for people with high-risk acute leukemias or myelodysplastic syndrome. Before a donor stem cell transplant, patients receive a radioactive antibody (211At-BC8-B10) designed to target and kill cancer cells while sparing healthy tissue. The goal…

This early-stage trial tests a special type of immune cell (CIML NK cells) combined with a low dose of IL-2 in people whose blood cancer (like AML or MDS) came back after a stem cell transplant. The goal is to find a safe dose and see if it can put the cancer back into remission.…

This early-phase trial tests whether specially trained natural killer (NK) cells, called CIML NK cells, along with interleukin-2 (IL-2), can safely prevent leukemia from coming back after a stem cell transplant. The study enrolls 15 adults with high-risk acute myeloid leukemia, m…

This early-stage trial tests a new drug, 8-chloro-adenosine, combined with the existing drug venetoclax in 30 adults with acute myeloid leukemia that has come back or not responded to treatment. The main goal is to check safety and find the best dose. Researchers hope this combin…

This phase II trial is testing whether adding the drug venetoclax to standard chemotherapy can improve remission rates in younger patients with intermediate-risk acute myeloid leukemia (AML). About 153 participants will receive either standard chemo or a combination with venetocl…

This early-phase study tests a new drug called SL-401 combined with two other drugs (azacitidine and venetoclax) in people with certain blood cancers—acute myeloid leukemia, myelodysplastic syndrome, and blastic plasmacytoid dendritic cell neoplasm. The main goal is to find the s…

This large phase 3 trial is testing whether a new formulation of two chemotherapy drugs (CPX-351) and a targeted drug called gilteritinib can improve outcomes for children and young adults with newly diagnosed acute myeloid leukemia (AML). The study compares these new approaches …

This early-phase trial tests whether adding a menin inhibitor (SNDX-5613) to standard chemotherapy can better control acute myeloid leukemia (AML) in people with certain gene changes (NPM1 or MLL). About 38 newly diagnosed adults will receive the combination to find the safest do…

This early-phase trial tests whether adding natural killer (NK) cells from a healthy donor to the standard drugs azacitidine and venetoclax can help control acute myeloid leukemia (AML). About 32 adults with relapsed or hard-to-treat AML will receive the combination. The main goa…

This early-stage trial is testing a new drug called cirtuvivint, alone or with another drug combo (ASTX727), in people with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML). The goal is to find the safest dose and check for side effects. About 54 participants whose…

This early-phase trial is testing a combination of two oral drugs—venetoclax and decitabine/cedazuridine—in children and teens whose acute myeloid leukemia (AML) has returned or not responded to prior treatment. The study aims to find the safest dose and check for early signs tha…

This early-phase trial tests a combination of three drugs—ziftomenib, venetoclax, and gemtuzumab—in children and young adults (ages 3 to 21) with acute myeloid leukemia that has come back or not responded to treatment. The main goal is to find a safe dose and check for side effec…

This phase 3 trial tests whether less intense drug combinations can control relapsed or refractory acute myeloid leukemia (AML) as well as high-dose chemotherapy. About 339 adults whose AML has returned or not responded to initial treatment will be randomly assigned to either a l…

This study combines three chemotherapy drugs (cladribine, idarubicin, cytarabine) with a targeted drug (quizartinib) to treat acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). It includes up to 80 adults who are newly diagnosed or whose cancer has returne…

This study tests a combination of three drugs—ASTX727, venetoclax, and gilteritinib—for people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome that has a FLT3 mutation. The drugs work in different ways to stop cancer cells from growing. The trial aims to f…

This early-stage study is testing an experimental drug called pivekimab sunirine in about 18 children whose acute myeloid leukemia (AML) has come back or not responded to standard treatments. The main goals are to check the drug's safety and how it moves through the body. Partici…

This study tests a new treatment for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has come back or not responded to standard therapy. The treatment uses specially engineered natural killer (NK) cells designed to recognize and attack cancer cells…

This phase II trial tests whether adding enasidenib to standard ASTX727 and venetoclax improves remission rates in older adults (or younger unfit patients) with newly diagnosed IDH2-mutated acute myeloid leukemia (AML). About 93 participants will be randomly assigned to receive e…

This Phase 2 trial tests whether adding venetoclax to a chemotherapy regimen of cladribine, low dose cytarabine, and azacitidine can improve remission rates in adults aged 50 and older with untreated acute myeloid leukemia. The study involves 145 participants and uses a two-stage…

This study tests a new oral drug called bleximenib for people with acute leukemia that has come back or not responded to treatment. The drug targets specific genetic changes in the cancer cells. The trial has two phases: first to find the safest dose, then to see how well it work…

This study tests whether giving donor white blood cells (lymphocytes) soon after a stem cell transplant can lower the chance of cancer returning in people with high-risk blood cancers like leukemia or lymphoma. Participants receive chemotherapy, a stem cell transplant, and then a…

This study tests a new all-oral combination of three drugs—SNDX-5613, ASTX727, and venetoclax—for people with acute myeloid leukemia (AML) or related leukemia. The first part finds the safest dose of SNDX-5613, and the second part checks if that dose helps control the disease. Ab…

This early-stage trial is testing an experimental drug called JNJ-95804306 in people with blood cancers like leukemia that have come back or not responded to standard treatments. The study has two parts: first, finding a safe dose, and then checking if the drug shrinks tumors whe…

This study tests a stem cell transplant method that removes certain immune cells (T-cells and B-cells) from the donor cells. The goal is to reduce graft-versus-host disease, a serious complication where donor cells attack the patient's body. The trial includes 20 children and you…

This early-stage trial is testing a new antibody drug called GEN3018 in people whose acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) has come back or stopped responding to treatment. The main goal is to check safety and find the right dose. Up to 78 parti…

This study tests a new drug called sonrotoclax combined with standard chemotherapy and other targeted medicines for adults newly diagnosed with acute myeloid leukemia (AML). About 205 participants will receive different treatments based on their genetic markers. The goal is to se…

This early-phase study tests whether adding hyperbaric oxygen therapy (breathing pure oxygen in a pressurized chamber) to standard stem cell transplant preparation is safe and helps recovery. It involves 24 adults with various blood cancers, such as leukemia and myelofibrosis. Th…

This study tests whether taking oral azacitidine pills for up to six months can help prevent leukemia from returning in patients who are eligible for a stem cell transplant but cannot get one due to racial or socioeconomic disparities. The trial enrolls 12 adults with acute myelo…

This study tests a stem cell transplant from half-matched (haploidentical) donors for people with various blood cancers. Before the transplant, patients receive chemotherapy and low-dose radiation to prepare their body. The goal is to replace diseased bone marrow with healthy don…

This study looks at how the cancer drug ASTX727 (decitabine and cedazuridine) works in people with moderate or severe liver problems. About 27 adults with certain blood cancers or solid tumors will take the drug for up to 8 weeks. The goal is to understand how the liver affects t…

This early-stage study looks at how the body handles the cancer drug ASTX727 (decitabine and cedazuridine) in people with severe kidney problems compared to those with normal kidneys. It includes 18 adults with acute myeloid leukemia, myelodysplastic syndromes, or solid tumors. T…

This study tests a combination of three drugs—olutasidenib, decitabine, and venetoclax—in people with acute myeloid leukemia (AML) that has a specific IDH1 gene mutation. The goal is to find a safe and effective dose for those whose cancer has returned or not responded to treatme…

This study tests whether the drug enasidenib can safely prevent leukemia from returning in 35 people with IDH2-mutated acute myeloid leukemia who have already had a donor stem cell transplant. Enasidenib works by blocking enzymes that cancer cells need to grow. The main goal is t…

This study tests whether adding the drug venetoclax to standard chemotherapy helps children and young adults with relapsed acute myeloid leukemia (AML) live longer. About 130 participants aged 29 days to 21 years will be randomly assigned to receive either chemotherapy alone or c…

This study is testing a combination of oral medications for acute myeloid leukemia (AML) that has returned or not responded to treatment. The drugs include decitabine/cedazuridine, venetoclax, and either ivosidenib or enasidenib. The goal is to see if this combination is safe and…

This phase 2 trial is testing a combination of four chemotherapy drugs—cladribine, idarubicin, cytarabine, and venetoclax—in people with acute myeloid leukemia, high-risk myelodysplastic syndrome, or blast-phase chronic myeloid leukemia. The goal is to see if this mix can kill ca…

This early-phase trial tests a new treatment called CD123-CAR T cells for children and young adults (up to age 21) with certain types of leukemia or related blood cancers that have come back or not responded to standard therapy. The treatment involves collecting the patient's own…

This phase II trial tests whether combining two drugs—azacitidine and pembrolizumab—can help people with Hodgkin's lymphoma that has come back or stopped responding to treatment. About 24 participants will receive both drugs by IV. The main goal is to see how many patients respon…

This early-phase trial tests a new immunotherapy for children and adults with acute leukemia that has come back or not responded after a donor stem cell transplant. The treatment uses specially engineered donor T cells designed to recognize and attack a protein called HA-1 found …

This early-phase trial tests whether adding a radioactive antibody (225Ac-DOTA-daratumumab) to standard chemotherapy and targeted radiation can safely improve the conditioning regimen before a donor stem cell transplant. The study includes 15 adults with high-risk acute myeloid l…

This early-phase trial is testing a new type of CAR-T cell therapy, called CD19-CAR.p40-T, in 10 adults with B-cell lymphoma, acute lymphoblastic leukemia, or acute myeloid leukemia that has come back or not responded to treatment. Participants receive chemotherapy followed by an…

This study tests whether removing a specific type of immune cell (naive T cells) from donor stem cells can prevent chronic graft-versus-host disease (GVHD) in children and young adults with blood cancers. GVHD occurs when donor cells attack the patient's body after a stem cell tr…

This study tests a new approach for adults with aggressive blood cancers (like AML) that are likely to return after standard treatment. Participants receive a combination of chemotherapy drugs (decitabine plus FLAG-Ida) and low-dose radiation, followed immediately by a stem cell …

This early-phase trial tests a new cell therapy for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who still have small amounts of cancer cells after standard treatment. The therapy uses the patient's own blood cells, armed with a special antibody to t…

This study tests a combination of two drugs, venetoclax and azacitidine, in about 100 adults in India with newly diagnosed acute myeloid leukemia (AML) who are not healthy enough for standard intensive chemotherapy. The goal is to see if the combo can put the cancer into remissio…

This study compares a new treatment (venetoclax plus CACAG) to the standard chemotherapy for adults newly diagnosed with intermediate- or high-risk acute myeloid leukemia (AML). About 160 participants aged 14 to 75 will be randomly assigned to one of the two groups. The main goal…

This study tests whether giving special 'memory-like' natural killer (NK) cells after a stem cell transplant can help prevent relapse in children and adults with high-risk acute myeloid leukemia (AML). The NK cells come from the same donor as the transplant and are boosted in the…

This early-phase trial is testing a new approach for acute myeloid leukemia (AML) that combines a personalized vaccine made from the patient's own immune and leukemia cells, specially trained T-cells, and two standard chemotherapy drugs. The study aims to see if this combination …

This phase II trial tests different drug combinations to prevent graft-versus-host disease (GVHD) in 400 blood cancer patients receiving stem cell transplants from unrelated donors. Participants will receive either thymoglobulin or a combination of cyclophosphamide with other imm…

This study tests whether giving two common heart medications (a beta blocker and an ACE inhibitor) before and during intensive chemotherapy can prevent heart damage in people newly diagnosed with acute myeloid leukemia (AML). About 70 adults will be randomly assigned to receive t…

This early-stage study tests a new oral drug, LP-118, in up to 100 adults with blood cancers like lymphoma, leukemia, or myeloma that returned or didn't respond to prior therapy. The main goals are to find the safest dose and see if the drug can shrink tumors or slow the disease.…

This study tests a combination of three drugs (bugitinib, venetoclax, and cytarabine) in adults with acute myeloid leukemia that has come back or not responded to treatment. The goal is to see if the treatment can clear hidden cancer cells from the bone marrow and keep them away.…

This study tests a personalized vaccine made from a patient's own leukemia cells to help prevent the cancer from coming back. It is for adults with acute myeloid leukemia who are in remission after chemotherapy. The vaccine is designed to train the immune system to recognize and …

This study is for adults newly diagnosed with a type of acute myeloid leukemia (non-M3). It tests whether adding silibinin, a natural compound from milk thistle that protects the liver, to standard chemotherapy can improve remission rates and survival. About 100 participants will…

This study looks at whether menin inhibitors can help prevent leukemia from coming back in patients who have had a stem cell transplant. About 20 adults with certain genetic types of acute leukemia will take these drugs as maintenance therapy. Researchers will track how many pati…

This study is testing an experimental oral drug called ASTX030 (a combination of azacitidine and cedazuridine) for people with certain blood cancers like myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and chronic myelomonocytic leukemia (CMML). The drug is given a…

This study tests whether a low-dose, weekly chemotherapy combination (decitabine and venetoclax) given after a bone marrow transplant can help prevent high-risk myeloid cancers like acute myeloid leukemia from coming back. About 20 participants will receive the treatment for up t…

This early-phase trial tests a stem cell therapy called Orca-T combined with targeted radiation and chemotherapy for people aged 60-75 with acute leukemias or myelodysplastic syndrome. The goal is to see if this approach is safe and can reduce side effects while effectively treat…

This phase 3 trial tests two drugs, Thymoglobulin and Grafalon, to see which one better prevents graft-versus-host disease (GVHD) in patients aged 50-70 with acute myeloid leukemia or myelodysplastic syndrome. All participants receive a stem cell transplant from a matched unrelat…

This program provides galinpepimut-S, a cancer vaccine that aims to train the immune system to fight cancer cells, to individual patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who have no other treatment options. It is for people who cannot join a cl…

This study is testing a new drug called BGB-11417 (sonrotoclax) in people with acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), or related blood cancers. The drug works by blocking a protein that helps cancer cells survive. The trial will give the drug alone or toge…

This early-stage trial is testing whether adding the drug talazoparib to standard chemotherapy is safe for children and young adults up to age 21 whose acute myeloid leukemia (AML) has returned or not responded to treatment. About 34 participants will receive different doses to f…

This study tests whether a new chemotherapy combination (TmBU) works better than the standard one (mBUCY) before a stem cell transplant in people with high-risk or hard-to-treat acute leukemia. About 48 patients aged 65 or younger will be randomly assigned to one of the two regim…

This early-stage trial tests a new drug called imetelstat combined with two standard chemotherapies for children and teens with acute myeloid leukemia, myelodysplastic syndrome, or juvenile myelomonocytic leukemia that has returned or not responded to treatment. The main goal is …

This study tests adding venetoclax to a standard chemotherapy regimen (CLAG-M) for people with acute myeloid leukemia (AML) or related high-grade blood cancers. The goal is to find the safest dose and see if the combination improves cancer control. About 62 participants will take…

This early-stage trial is testing a new drug called ziftomenib combined with standard chemotherapy or another targeted drug for people with relapsed or treatment-resistant acute myeloid leukemia (AML) that has specific genetic changes. The main goal is to see if these combination…

This phase 2 trial is testing a combination of three drugs—olutasidenib, venetoclax, and azacitidine—in adults aged 18-75 with newly diagnosed acute myeloid leukemia that has a specific IDH1 gene mutation. The study aims to see if this combo is safer and works better than standar…

This phase 2 trial tests a stem cell transplant using a milder chemo and radiation regimen for people with blood cancers like AML and MDS. The goal is to see if this approach improves survival at 100 days after transplant. Participants receive donor stem cells along with drugs to…

This study tests whether a drug called sargramostim can help restore white blood cells as quickly as the standard drug (G-CSF) after a half-matched stem cell transplant for blood cancers, while possibly lowering the risk of serious infections. About 38 adults with blood cancers l…

This phase 2 trial tests a drug called olutasidenib combined with other targeted therapies for people with relapsed or hard-to-treat blood cancers that have a specific IDH1 mutation plus other signaling mutations. The study aims to see how safe and tolerable these drug combinatio…

This study tests the drug ponatinib in children aged 1 to 18 with advanced leukemias, lymphomas, or solid tumors that have come back or not responded to standard treatment. The goal is to find safe doses and see if the drug can shrink tumors or improve blood counts. About 70 chil…

This study tests whether a stem cell transplant from a donor can help people with a high-risk type of acute myeloid leukemia (AML) stay cancer-free longer. Participants receive the transplant after initial chemotherapy. The trial tracks survival, relapse, and side effects in 90 n…

This early-stage trial tests an experimental oral drug called GLB-001 in adults whose acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS) have come back or not responded to treatment. The study aims to find a safe dose and see if the drug shows any signs of …

This study tests whether two drugs, venetoclax and revumenib, can control minimal residual disease (MRD) in people with acute myeloid leukemia (AML). MRD means small numbers of cancer cells remain after initial treatment, raising the risk of relapse. The trial enrolls about 8 par…

This study tests a new mix of drugs for people newly diagnosed with a specific type of acute myeloid leukemia (AML). The treatment combines a targeted drug (venetoclax) with two chemotherapy drugs, then switches to another chemo drug plus venetoclax. The goal is to see if this ap…

This study tests an experimental drug called CTX-712 in people with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) that have come back or not responded to treatment. The drug is taken by mouth once or twice weekly. The trial aims to find the safest dose and see i…

This study tests a device that removes specific immune cells from donated stem cells before transplant. The goal is to lower the risk of graft-versus-host disease, where donor cells attack the patient's body. Up to 90 children and young adults (ages 0-30) will receive these treat…

This early-stage study tests a new drug, BMS-986497, in people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has returned or not improved after prior treatments. The drug is given alone or combined with standard medicines (azacitidine and venetoclax). T…

This early-stage trial is testing whether adding high-dose vitamin C (given through an IV) to the usual two-drug combination (azacitidine and venetoclax) is safe and effective for people newly diagnosed with acute myeloid leukemia who cannot handle intensive chemotherapy. About 3…

This study tests a new combination of three drugs (tagraxofusp, azacitidine, and venetoclax) for people with a type of acute myeloid leukemia (AML) that has returned or not responded to previous treatment. The goal is to see if this combination can help more patients achieve remi…

This phase 3 trial tests whether adding the drug bleximenib to standard chemotherapy helps adults with a certain genetic type of acute myeloid leukemia (AML). About 875 people will get either bleximenib or a placebo alongside chemo, then be followed for 4 years. The goal is to se…

This study tests whether adding a precise, targeted form of radiation to the standard chemotherapy and stem cell transplant can kill more cancer cells in the bone marrow and reduce the chance of relapse. About 27 adults with acute leukemia or myelodysplastic syndrome (MDS) will r…

This early-phase study tests a new drug called SEA-CD70, alone or with standard drugs azacitidine and venetoclax, in people with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). The main goal is to check safety and find the right dose. About 178 participants will b…

This trial tests whether a lower dose of total body irradiation (200 cGy) before a bone marrow transplant works as well as a standard higher dose (400 cGy) for people with acute leukemia. The goal is to see which dose leads to fewer severe side effects like graft-versus-host dise…

This study tests a special stem cell transplant for children and adults with blood cancers like leukemia. The transplant uses stem cells that have had certain immune cells removed to lower the risk of graft-versus-host disease, a serious complication. About 70 participants will r…

This early-stage trial is testing a new type of immunotherapy for people with CD30-positive blood cancers that have come back or not responded to treatment. The therapy uses a patient's own immune cells, which are collected, modified with a special antibody, and then given back t…

This early-phase trial is testing a new drug called Debio 1562M in about 134 people with acute myeloid leukemia (AML) that has come back or not responded to other treatments. The study first checks safety and finds the right dose, then looks at whether the drug can shrink the can…

This early-phase study tests a new treatment called CER-1236 for people with certain blood cancers (acute myeloid leukemia, myelodysplastic syndrome, or myelofibrosis) that have not responded to standard therapy. The treatment uses a patient's own immune cells, which are modified…

This phase 2 trial tests whether a newer chemotherapy drug called CPX-351 works better than standard chemo for adults aged 50 and older with a hard-to-treat form of acute myeloid leukemia (AML). About 248 people will be randomly assigned to receive either CPX-351 or standard chem…

This study tests an experimental drug called LBS-007 in adults with acute leukemias (AML or ALL) that have returned or not responded to standard treatments. The main goals are to find a safe dose and see if the drug can control the disease. About 90 participants will receive the …

This early-phase trial tests a new drug called revumenib alongside standard chemotherapy and another targeted drug (midostaurin) for adults newly diagnosed with acute myeloid leukemia (AML) that has specific genetic changes (NPM1 and FLT3 mutations). The study aims to find a safe…

This early-phase trial tests whether giving patients extra gamma delta T-cells—a type of immune cell that can kill cancer—after a half-matched bone marrow transplant can improve outcomes. The study includes up to 38 adults with leukemia or myelodysplastic syndromes. The goal is t…

This early-stage study is testing a new drug called RPT1G in 24 adults whose acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS) have not responded to standard treatments or have returned. The main goals are to see if the drug is safe and to find the best do…

This phase 2 trial is testing a new combination of chemotherapy, radiation, and immune-suppressing drugs for people aged 18-65 with blood cancers who need a stem cell transplant. The goal is to see if this regimen improves survival one year after transplant. About 209 participant…

This early-phase study tests an investigational drug called ziftomenib in adults with acute myeloid leukemia (AML) who have had a stem cell transplant. The goal is to find a safe dose and see if the drug can help prevent the cancer from coming back. About 22 participants will tak…

This study tests whether adding chidamide to the standard venetoclax and azacitidine (VA) regimen can help people with acute myeloid leukemia (AML) who did not improve after one cycle of VA alone. About 32 adults aged 18 or older who are not candidates for intensive chemotherapy …

This study tests an oral drug called revumenib in people with certain types of leukemia that have relapsed or not responded to standard therapy. The trial has two parts: first, finding the best dose, then testing that dose in four groups based on leukemia type. About 447 particip…

This early-phase study tests whether giving specially trained immune cells (CIML NK cells) along with a targeted drug (venetoclax) can safely help prevent acute myeloid leukemia (AML) from coming back. Ten adults with AML who have already received standard treatment will receive …

This early-phase trial is testing whether combining two drugs—decitabine/cedazuridine (already approved for MDS) and the experimental drug defactinib—is safe and tolerable for people with high-risk myelodysplastic syndromes, certain acute myeloid leukemias, and chronic myelomonoc…

This study tests whether giving two drugs, decitabine and filgrastim, after a stem cell transplant can help prevent blood cancers like AML and MDS from coming back in children and young adults. About 37 participants will receive the drug combination for up to 6 cycles. The main g…

This phase 2 trial tests a reduced-intensity chemotherapy regimen (fludarabine, busulfan, melphalan) before stem cell transplant in 61 patients aged 55 and older with myeloid cancers like AML, MDS, or CMML. The goal is to see if this gentler approach can improve disease-free surv…

This study tests whether a maintenance therapy using a hypomethylating agent (HMA) can help prevent relapse and improve survival in people with favorable risk acute myeloid leukemia (AML). About 77 participants who are already in remission after initial treatment will receive HMA…

This early-stage trial is testing an oral drug called BY002 in 18 adults with relapsed or refractory acute leukemia that has specific genetic changes (KMT2A rearrangements or NPM1 mutations). The main goals are to check the drug's safety, find the best dose, and see if it can shr…

This study tests a new way to do stem cell transplants for children with blood cancers like leukemia. It uses a half-matched family donor and removes certain immune cells from the donated cells to lower risks. The goal is to see if this method is safe and helps the child's body a…

This study tests whether giving a chemotherapy drug (decitabine) plus a targeted therapy (ruxolitinib, fedratinib, or pacritinib) before a stem cell transplant helps people with advanced myeloproliferative neoplasms (MPN) get to transplant and have better outcomes. About 25 adult…

This early-stage trial is testing an experimental drug called ziftomenib alongside standard treatments for acute myeloid leukemia (AML) in people with specific gene mutations. About 420 participants with newly diagnosed or relapsed AML will be assigned to one of three treatment a…

This study looks at whether people with acute myeloid leukemia (AML) who have responded well to a year of treatment with venetoclax and azacitidine can safely stop taking these drugs. Researchers will monitor 50 patients closely for signs of relapse and compare them to a similar …

This study tests a combination of three drugs—ivosidenib, venetoclax, and azacitidine—in people with blood cancers like acute myeloid leukemia (AML) that have a specific IDH1 mutation. The goal is to see if the combo is safe and works better than current treatments. About 96 adul…

This study is monitoring the safety and effects of Mylotarg in 165 adults in Korea who are newly diagnosed with acute myeloid leukemia (AML). Participants will receive Mylotarg as part of their routine care, and researchers will track any side effects and how the disease responds…

This phase II trial is testing two different methods to reduce graft-versus-host disease (GVHD) in patients with acute leukemia or myelodysplastic syndrome (MDS) who are receiving a donor stem cell transplant. One method removes certain immune cells from the donor cells before tr…

This phase 2 trial is testing the drug dasatinib alone in adults with acute myeloid leukemia (AML) whose cancer did not respond to the usual combination of venetoclax and azacitidine. The main goal is to see if dasatinib can shrink the leukemia after two months of treatment. Abou…

This early-phase study tests a new treatment called ADCLEC.syn1 CAR T cells for adults with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. The main goal is to find a safe dose that causes few side effects, and then see if it can help control…

This study is for adults with a specific type of acute myeloid leukemia (CD123+ AML) who cannot receive standard strong chemotherapy. It tests a new drug, tagraxofusp, added to two other drugs (venetoclax and azacitidine) to see if it helps more people achieve complete remission.…

This phase 2 trial tests whether giving olutasidenib with azacitidine, followed by olutasidenib alone as maintenance, can keep acute myeloid leukemia (AML) with an IDH1 mutation from returning. The study enrolls 28 adults who have already achieved remission after initial treatmen…

This early-stage trial is testing whether a drug called olutasidenib can safely prevent blood cancers (AML, MDS, or CMML) from coming back after a donor stem cell transplant. About 15 adults with a specific gene mutation (IDH1) will take the drug daily for up to two years. The ma…

This early-phase trial tests whether combining tagraxofusp (a drug that targets CD123 on cancer cells) with azacitidine (a drug that helps bone marrow make normal cells) can safely prevent relapse in people with CD123-positive acute myeloid leukemia or myelodysplastic syndrome af…

This early-stage trial is testing whether adding two drugs, decitabine and venetoclax, to a standard reduced-intensity stem cell transplant can safely help control high-risk myeloid cancers like acute myeloid leukemia. About 20 adults aged 18-75 with a matched donor will receive …

This phase 2 study tests whether a three-drug combination (ivosidenib, azacitidine, and venetoclax) followed by maintenance therapy with ivosidenib alone can prevent acute myeloid leukemia (AML) from coming back in patients with an IDH1 mutation. The trial enrolls 45 people aged …

This early-stage trial tests a new treatment for acute myeloid leukemia that has returned or not responded to standard therapy. The treatment uses a patient's own immune cells, modified in a lab to recognize and attack leukemia cells. The study aims to find the safest dose and un…

This early-stage trial tests a combination of three drugs—pembrolizumab, decitabine, and venetoclax—in people with acute myeloid leukemia or myelodysplastic syndrome that has returned or not responded to treatment. The goal is to find the safest dose and see how well the drugs wo…

This early-phase trial tests a drug called revumenib in people with acute leukemia who have had a stem cell transplant. The drug targets a protein that helps leukemia cells grow. The study will check safety, find the best dose, and see if it can stop the cancer from coming back. …

This study tests a daily pill called olutasidenib given after a stem cell transplant to people with certain blood cancers (like AML or MDS) that have an IDH1 mutation. The goal is to see if the drug is safe and tolerable as maintenance therapy. About 31 participants will take the…

This early-stage trial is testing a new drug called FHD-286 combined with two standard chemotherapy drugs (decitabine and venetoclax) in 33 people with acute myeloid leukemia that is either newly diagnosed with high-risk features or has returned after one prior treatment. The mai…

This phase 2 trial tests a three-drug combination (venetoclax, azacitidine, and homoharringtonine) followed by a stem cell transplant in 56 adults aged 18-55 with newly diagnosed, intermediate- or high-risk acute myeloid leukemia (AML). The goal is to see if this approach improve…

This early-stage trial is testing whether two drugs that lower metal levels in the body can help people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) respond better to chemotherapy. The study will enroll 58 adults and aims to find the safest dose and check f…

This study looks at whether people with acute myeloid leukemia (AML) who have been on a combination of azacitidine or decitabine plus venetoclax for a year can stop treatment if tests show no remaining cancer cells. Researchers want to see if these patients can stay in remission …

This early-phase trial is testing the safety of combining two drugs—Vyxeos and gemtuzumab ozogamicin—for adults newly diagnosed with acute myeloid leukemia. Researchers want to find the best dose that doesn't cause severe side effects. The study will also look at how many patient…

This study tests whether specially trained immune cells from a half-matched donor can safely treat acute myeloid leukemia (AML) that has come back or not responded to standard treatment. About 20 people aged 2 and older will receive an infusion of these cells. The main goal is to…

This early study is testing whether bone marrow from deceased donors can be safely used for transplants in people with blood cancers like leukemia and lymphoma. Twelve patients will receive the transplant along with chemotherapy or radiation. The main goal is to see if the new ma…

This phase 2 trial tests whether low-dose azacitidine can help maintain donor cell levels (chimerism) in patients with MDS, AML, or related blood cancers after an allogeneic stem cell transplant. About 43 adults whose donor cell levels are dropping will receive azacitidine for at…

This study tests whether giving children with leukemia a special type of donor immune cell (CD45RA-depleted) after a stem cell transplant can help their immune system recover faster and lower the risk of serious viral or fungal infections. The trial enrolls 50 children under 25 w…

This early-phase study tests a new drug called rezatapopt combined with the standard drug azacitidine in 24 adults with a specific type of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has a TP53Y220C mutation. The main goal is to check safety and find the b…

This clinical trial is testing whether adding the drug venetoclax to standard chemotherapy before a stem cell transplant can improve outcomes for people with high-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The study will enroll 324 participants and aims …

This study tests a combination of two drugs, azacitidine and enasidenib, in people with a high-risk blood cancer called myelodysplastic syndrome (MDS) that has a specific genetic change (IDH2 mutation). The goal is to see if the drugs can stop cancer growth and improve outcomes. …

This early-stage trial tests two oral drugs, ziftomenib and quizartinib, together in adults with relapsed or hard-to-treat acute myeloid leukemia (AML) that has certain genetic markers. The goal is to find a safe and effective all-pill treatment for common AML subtypes. About 44 …

This study tests a new drug called STX-0712 in people with advanced types of blood cancer (CMML or AML) who have run out of standard treatments. The main goal is to find a safe dose and see how the body handles the drug. About 105 participants will take part in this early-phase t…

This early-phase trial tests whether the drug olutasidenib can safely help people with a specific genetic form of acute myeloid leukemia (IDH1-mutant AML) stay in remission after standard chemotherapy. About 15 participants will take the drug twice daily. The main goals are to se…

This phase 2 trial tests a personalized approach to stem cell transplants for people with blood cancers like leukemia and lymphoma. Instead of a one-size-fits-all chemotherapy and radiation regimen, doctors adjust the doses based on each patient's risk. The goal is to improve the…

This study tests a new treatment for adults with a specific type of acute myeloid leukemia (FLT3-ITD AML). The goal is to see if a combination of targeted drugs (gilteritinib, venetoclax, azacitidine) followed by high-dose chemotherapy can control the disease well enough to avoid…

This early-phase trial is testing whether a long-acting antibiotic called dalbavancin, given once every 28 days along with a short course of oral antibiotics, can prevent serious bloodstream infections in children and young adults with high-risk leukemia. The study will enroll 29…

This early-phase study tests a new drug called RJK-RT2831 in 71 adults with blood cancers. The main goals are to check safety, find the right dose, and see if the drug shows any early signs of working. Participants must be 18 to 74 years old and in good enough health to follow th…

This pilot study tests a new treatment plan for adults aged 60 and older with high-risk acute myeloid leukemia (AML) or similar blood cancers. The plan combines a strong chemotherapy regimen (FLAG-Ida) with a lower-intensity stem cell transplant just a few days later. The goal is…

This study tests a drug called romiplostim N01 in 130 blood cancer patients receiving a stem cell transplant from a half-matched donor. The drug is given weekly for up to 4 weeks to help platelets recover faster, reducing the need for transfusions and bleeding risk. Half the pati…

This phase 1 study is testing a combination of three drugs—ziftomenib, venetoclax, and azacitidine—in children and young adults (ages 2 to 21) with acute leukemia that has returned or not responded to treatment. The main goal is to find the safest dose of ziftomenib when given wi…

This study tests whether a targeted drug called gemtuzumab ozogamicin can clear tiny amounts of leukemia that remain after initial treatment in adults with acute myeloid leukemia (AML). The drug works like a smart bomb, attaching to a protein on cancer cells and delivering a chem…

This early-phase trial tests whether infusing specially designed immune cells can prevent blood cancer from coming back after a stem cell transplant. The cells target a specific protein (HLA-DPB1*04:01) found on many cancer cells and include a 'suicide switch' to turn them off if…

This phase 2 trial is testing whether adding the targeted drug venetoclax to a standard chemotherapy regimen (FLAG IDA) works better than the usual treatment for adults newly diagnosed with acute myeloid leukemia (AML). About 102 participants will receive either the new combinati…

This study tests a special cord blood transplant for people with high-risk blood cancers like leukemia and lymphoma. Participants get chemotherapy and radiation before the transplant to kill cancer cells and prepare the body. After the transplant, drugs are given to prevent the n…

This phase 1 trial tests an oral chemotherapy drug (decitabine) alone or combined with other targeted drugs to prevent acute myeloid leukemia (AML) from coming back in patients who are already in remission. About 125 adults whose AML is under control but who are not ready for a s…

This early-stage study tests whether adding mitoxantrone to the usual venetoclax+azacitidine regimen can help adults with acute myeloid leukemia (AML) whose cancer did not respond or came back after initial treatment. About 30 participants will receive different doses to find the…

This early-phase trial is testing a new type of immune cell therapy called FOLR1 CAR T cells for children aged 6 and under with acute myeloid leukemia (AML) that has come back or not responded to treatment. The therapy involves taking a child's own immune cells, modifying them in…

This study is testing a combination of three drugs—quizartinib, decitabine, and venetoclax—in people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome. The goal is to find the safest dose and see if the combination improves remission rates. The trial is for …

This early-stage trial is testing a combination of two oral drugs—bomedemstat and venetoclax—in adults whose acute myeloid leukemia (AML) has returned or not responded to standard treatment. The main goal is to find the safest dose and check for side effects. Up to 18 participant…

This early-phase trial is testing whether adding the targeted drug venetoclax to standard chemotherapy can safely treat adults newly diagnosed with acute myeloid leukemia or advanced myelodysplastic syndrome. About 99 participants will receive different doses of venetoclax alongs…

This early-phase study tests whether a special cell therapy called T-allo10 can safely help rebuild the immune system in children and young adults (up to age 45) with blood cancers who have received a stem cell transplant. The treatment is given after the transplant to speed up r…

This early-stage trial is testing an experimental oral drug called MRX-2843 in adolescents and adults whose acute leukemia (AML, ALL, or mixed phenotype) has returned or not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and s…

This phase 2 trial tests a low-dose weekly schedule of two drugs, decitabine and venetoclax, in people with myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), or chronic myelomonocytic leukemia (CMML). The goal is to see if this gentler approach reduces treatment dela…

This phase 2 trial tests a combination of three drugs—venetoclax, cladribine, and low-dose cytarabine—in 68 adults aged 16-70 with acute myeloid leukemia that has returned or not responded to prior treatment. The goal is to see if this cocktail can shrink or eliminate leukemia ce…

This early-stage study tests a new treatment called SC-DARIC33 for children and young adults up to age 30 whose acute myeloid leukemia (AML) has returned or not responded to standard therapy. The treatment uses the patient's own immune cells, which are modified in the lab to bett…

This early-phase trial tests the safety of a new drug called karonudib in up to 9 adults with blood cancers like leukemia who have no standard treatment options left. The study aims to find a safe dose and look for any signs that the drug works. It is too early to know if karonud…

This phase 2 trial tests a combination of two drugs, cladribine and venetoclax, in 20 adults with a specific form of acute myeloid leukemia (monocytic AML) that has stopped responding to or returned after standard treatment. The goal is to see if this new combo can shrink or elim…

This phase 1 trial is testing whether adding the targeted drug pemigatinib after standard chemotherapy can help people with newly diagnosed acute myeloid leukemia (AML). Pemigatinib blocks a protein called FGFR that may fuel leukemia growth. The study will enroll 32 adults with i…

This study tests whether a genetic test can help decide which leukemia patients need a strong antifungal drug (posaconazole) to prevent serious mold infections during chemotherapy. About 410 adults with acute myeloid leukemia will be randomly assigned to receive the drug or a pla…

This study tests whether giving extra natural killer (NK) cells from a donor can safely help prevent leukemia or MDS from coming back after a stem cell transplant. About 10 adults with acute myeloid leukemia or myelodysplastic syndromes who don't have a fully matched donor will r…

This clinical trial tests whether infusions of donor natural killer (NK) cells, given before and after a stem cell transplant, can safely prevent leukemia from coming back in children and young adults with hard-to-treat acute leukemia. The study enrolls 15 patients aged 0 to 25 w…

This global phase 3 trial tests whether adding the experimental drug lisaftoclax to standard azacitidine helps older adults with newly diagnosed acute myeloid leukemia (AML) live longer. About 486 participants who cannot have intensive chemotherapy will receive either the combo o…

This study tests a combination of a PD-1 inhibitor (camrelizumab), a chemotherapy drug (azacitidine), and donor immune cells (DLI) in 43 adults with acute myeloid leukemia that has returned after a stem cell transplant. The goal is to see if this approach can help patients achiev…

This study compares a new drug combination (ABC-14) with two standard treatments for adults newly diagnosed with acute myeloid leukemia (AML). About 240 participants will receive either ABC-14, the traditional "3+7" chemotherapy, or a two-drug combo (AB-14). The goal is to see wh…

This early-stage study tests a drug called danvatirsen, first by itself and then combined with venetoclax, in 38 adults with relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). The goal is to see if the treatment is safe and can shrink or contr…

This early-phase trial is testing two new chemotherapy combinations for children and young adults with acute myeloid leukemia (AML) who are at intermediate or high risk of relapse. The goal is to see if these combinations are tolerable and can achieve similar or better survival w…

This study tests whether adding the drug ruxolitinib to the usual anti-rejection medicines (tacrolimus and methotrexate) can prevent graft-versus-host disease (GVHD) in children and young adults getting a stem cell transplant for leukemia or myelodysplastic syndrome. GVHD happens…

This phase 2 trial tests a two-step, lower-intensity transplant method for people with various blood cancers. The goal is to see if this gentler approach reduces the chance of dying from the transplant itself. About 63 participants will receive a combination of radiation, chemoth…

This early-phase trial tests a new type of stem cell transplant for children with blood cancers or solid tumors that have relapsed or not responded to standard treatment. Doctors use a half-matched donor's stem cells, specially filtered to remove certain immune cells, and give th…

This phase 2 trial tests whether combining interferon-gamma (a protein that boosts the immune system) with donor immune cells can help patients whose acute myeloid leukemia or myelodysplastic syndromes have returned after a stem cell transplant. The study will enroll 45 adults an…

This phase 2 trial tests whether a new way of giving anti-thymocyte globulin (ATG) along with standard drugs tacrolimus and methotrexate can prevent acute graft-versus-host disease (GVHD) after a stem cell transplant. The study enrolls 29 adults aged 18-60 with blood cancers who …

This phase 2 trial tests a two-step dosing schedule of anti-thymocyte globulin (ATG) combined with standard drugs (tacrolimus and mini methotrexate) to prevent severe graft-versus-host disease (GVHD) in 56 adults with blood cancers like acute leukemia. Participants receive ATG on…

This early study tests an experimental oral drug called HMPL-506 in about 132 adults with specific types of leukemia (AML or ALL) that have come back or not responded to treatment. The main goal is to check safety and find the right dose. Researchers will also look for signs that…

This study tests whether using a simple early warning score (NEWS) to quickly move high-risk blood cancer patients to the ICU can reduce deaths and organ failure. Over 2,200 adults receiving intensive chemotherapy or stem cell transplants will take part across ten hospitals. Half…

This study tests whether adding the targeted drug venetoclax to standard chemotherapy before a stem cell transplant can help prevent cancer from returning in people with high-risk acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). About 138 participants aged 12 to 6…

This phase 2 trial tests whether a combination of venetoclax and azacitidine can clear measurable residual disease (MRD) in adults with acute myeloid leukemia (AML) who still have or develop leftover cancer cells after initial chemotherapy, and before a stem cell transplant. Abou…

This study is testing whether adding two targeted drugs, midostaurin and gemtuzumab ozogamicin, to standard chemotherapy can help people with newly diagnosed acute myeloid leukemia (AML) who have certain genetic changes. About 214 participants will receive the combination in two …

This study tests a combination of drugs (venetoclax plus azacitidine, decitabine, or cytarabine) without traditional anthracycline chemotherapy in 40 adults newly diagnosed with a specific genetic subtype of acute myeloid leukemia (CBFβ::MYH11-positive). The goal is to see if thi…

This study is testing a new radioactive tracer called 68Ga-EV203 for PET/CT scans in people with blood cancers like multiple myeloma, lymphoma, and leukemia. The goal is to see how the tracer spreads in the body, how much radiation it gives off, and whether it can find tumors bet…

This study tests whether advanced scans (PET/MR, PET/CT, and whole-body MR) can find leukemia that has spread outside the bone marrow in people newly diagnosed with acute myeloid leukemia (AML). About 77 participants will receive these scans to see how well they detect hidden dis…

This early-phase trial tests a vaccine (CMV-MVA Triplex) given to both stem cell donors and recipients to boost immunity against cytomegalovirus (CMV) and prevent active infection after a half-matched stem cell transplant. About 46 people with various blood cancers will take part…

This phase 3 trial tests whether xylitol dental wipes can reduce bloodstream infections in children with acute myeloid leukemia (AML). Xylitol, a natural sugar that limits mouth bacteria growth, is applied via wipes during chemotherapy. The study will compare infection rates betw…

This phase 2 trial tests a vaccine called CMV-MVA Triplex, given to stem cell donors before they donate. The goal is to boost the donor's immunity against cytomegalovirus (CMV), which can then be passed to the transplant patient. Researchers hope this will prevent CMV infection i…

This study tests whether a drug called dexrazoxane can protect the heart from damage caused by chemotherapy in people with certain blood cancers, such as acute myeloid leukemia and high-risk myelodysplastic syndrome. About 100 participants will receive dexrazoxane alongside stand…

This study tests whether tranexamic acid (TXA), a drug that prevents blood clots from breaking down, can safely reduce bleeding in people with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML). About 75 outpatients receiving less-intensive chemotherapy will be rando…

This study tests a program called Nite2Day+ that uses mindfulness and sleep tips to help people with blood cancers sleep better and manage fatigue, stress, and pain. About 60 adults hospitalized for treatment will either get the program or standard care. The program includes a mo…

This study tests whether regular massage therapy can improve sleep for children aged 12-21 who are hospitalized for cancer treatment or stem cell transplant. Seventy participants will either receive standard care or a 20-30 minute massage five days a week for three weeks. Sleep w…

This study tests a program called EASE that combines psychological support with regular symptom checks and early access to palliative care. Researchers want to see if it reduces traumatic stress and physical symptoms in people newly diagnosed with acute leukemia. Half of the 266 …

This study tests whether giving blood transfusions at home is practical and acceptable for cancer patients who need regular transfusions. About 30 adults with blood cancers or bone marrow failure will receive 1-5 blood product units at home. Researchers will track how often trans…

This study tests a new way to screen patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) by analyzing their bone marrow and blood for specific biomarkers. The goal is to quickly match patients with a treatment trial that targets their cancer's unique mark…

This observational study examines a specific group of patients with a type of acute myeloid leukemia (AML) that has an NPM1 mutation. Researchers want to see if a particular subset, called APL-like, is linked to early blood vessel problems like bleeding or clots. The study will l…

This study screens children and young adults up to age 22 whose leukemia has returned or is hard to treat. By testing their blood and bone marrow, doctors can identify specific genetic markers to match them with the most promising experimental treatments. The goal is to build a r…

This study aims to safely collect health information like heart rate and activity levels from cancer patients using devices like smartphones and wearables. Researchers will use this data to learn more about how it relates to cancer diagnosis, treatment response, and risk factors.…

This study looks at blood cells from 20 adults with acute myeloid leukemia (AML) whose cancer returned after a stem cell transplant. All participants have specific genetic changes (NPM1 mutations or KMT2A rearrangements) and are being treated with a menin inhibitor. Researchers w…

This pilot study is testing whether fecal microbiota transplantation (FMT) — giving processed stool from a healthy donor via enema — is safe and doable in 20 patients with lymphoma or leukemia who are receiving CAR-T therapy or stem cell transplants. The goal is to see if at leas…

This study looks at whether adults with acute myeloid leukemia (AML) who are not healthy enough for strong chemotherapy are willing to let a computer randomly assign them to either lower- or higher-intensity treatment. The goal is to see if this approach is acceptable to patients…

This study collects blood and bone marrow samples from 80 adults newly diagnosed with acute myeloid leukemia (AML). Researchers will measure inflammasome activity before and after standard chemotherapy to see if it relates to how well the treatment works. The goal is to better un…

This early-stage study with 10 adults with acute leukemia looks at how the body absorbs, breaks down, and gets rid of the drug bleximenib. Participants take a radioactive version of the drug so researchers can track it in urine and stool. The goal is to understand the drug's path…

This study tracks T-cell changes in 250 acute myeloid leukemia patients receiving a stem cell transplant. By analyzing blood samples with advanced gene sequencing, researchers hope to understand if the immune system plays a key role in recovery and complications. The goal is to f…

This study collects blood and tissue samples from 2000 people—some with cancer and some without—to create a blinded reference set. Researchers will use these samples to evaluate how well new blood tests can detect many types of cancer early. The goal is to improve the accuracy of…

This study looks at whether extra financial help (called financial navigation) can reduce money-related stress and improve quality of life for people being treated for acute myeloid leukemia (AML). About 120 adults aged 18-64 starting intensive chemotherapy will be split into two…

This study looks at how the drug venetoclax behaves in the bodies of 100 adults with acute myeloid leukemia (AML). Researchers will take extra blood samples to measure drug levels and see how they relate to treatment success. The study does not change the patient's regular care a…

This study follows people with a gene change (DDX41) that raises the risk of blood cancers like MDS and AML, along with their family members. Researchers will collect health information and samples over 10 years to learn how these inherited risks lead to cancer. No treatment is g…

This study looks for inherited gene mutations that may raise the risk of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Researchers will use advanced genetic testing to compare DNA from affected and unaffected family members. The goal is to find new or known mu…

This study is not a treatment itself but a research method. It will collect data from nearly 2,000 older adults (60-75) with acute myeloid leukemia (AML) to compare a new drug combination (venetoclax plus decitabine) against standard intensive chemotherapy. Using AI and statistic…

This study tests whether a special PET scan (18F FLT) can detect signs of leukemia or myeloma after treatment. About 60 people aged 4 to 80 with relapsed or hard-to-treat blood cancers will get the scan before and after therapy. Researchers will compare the scan results with stan…

This study looks at 60 adults with acute myeloid leukemia or related blood cancers who are receiving a gentler type of chemotherapy. Researchers will measure certain proteins in the blood to see if they can predict how well the treatment works. The goal is to better understand wh…

This study aims to understand exactly how the drug interferon attacks cancer stem cells in people with myeloproliferative neoplasms (MPNs), a group of blood cancers. Researchers will analyze blood samples from 80 adults to see why some patients respond well while others do not. T…

This study collects stored cord blood from 300 children diagnosed with leukemia and checks for the same cancer mutations found in their tumor samples. Researchers want to understand how and when these mutations first appear before birth. The goal is to eventually develop a screen…

This study tests a telehealth program that helps older adults (60+) with blood cancers like leukemia or MDS talk to their doctors about their care wishes. The program also helps them fill out advance directive forms. Researchers want to see if it improves communication and reduce…

This study is collecting blood and bone marrow samples from 80 adults with acute myeloid leukemia (AML) who are starting treatment with azacitidine plus venetoclax. Researchers want to understand how the immune system responds to this chemotherapy combination. The goal is to find…

This study is for people with neuroendocrine tumors who are about to receive or have already received peptide receptor radionuclide therapy (PRRT). Researchers want to find out if certain genetic changes in the blood can predict who might later develop myelodysplastic syndrome (M…

This study looks at memory, concentration, and language problems caused by chemotherapy in people with blood cancers like leukemia and lymphoma. Researchers will compare 120 patients to their healthy relatives using tests and questionnaires before and after treatment. The goal is…

This study looks at whether giving blood transfusions only when hemoglobin drops below 7 gm/dL (instead of 9 gm/dL) is safe and maintains quality of life in leukemia patients after chemotherapy or stem cell transplant. About 50 adults with certain blood cancers will be randomly a…

This study is creating a large database of people in China with various blood diseases, such as leukemia, multiple myeloma, and hemophilia. Researchers will collect information from medical records and follow participants over time to learn about disease patterns, treatments, and…

This study is collecting genetic and drug sensitivity data from 300 children with leukemia to better understand why some cases relapse and how to target them more precisely. Researchers will analyze tumor DNA, gene activity, and test drugs on patient cells in the lab. The goal is…

This study is looking at whether certain carbohydrates in food, called FODMAPs, are related to graft-versus-host disease (GVHD) in people who have had a bone marrow transplant. GVHD is a common complication where donor cells attack the patient's body. Researchers will track 100 t…

This study looks at whether detecting leftover leukemia stem cells in the blood or bone marrow after chemotherapy can better predict if a child's leukemia will come back. About 283 children with newly diagnosed acute myeloid leukemia will be followed. The goal is to improve relap…

This study looks at how metabolism in cancer and immune cells influences the bone marrow environment and treatment resistance in blood cancers like leukemia and myelofibrosis. Researchers will analyze samples from 350 participants to measure metabolites, lipids, and gene activity…

This study creates a registry of 5,000 adults aged 50 and older with blood cancers like multiple myeloma and lymphoma. Researchers will track frailty, muscle loss, and other age-related health issues to better understand this group's needs. The goal is to gather information that …

This study looks at bone marrow cells from children with acute leukemia and compares them to cells from children without blood diseases. The goal is to understand why some leukemias relapse or resist treatment. Researchers will measure how these cells use energy and handle stress…

This study is testing a new whole genome sequencing approach called ChromoSeq for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Researchers want to see if ChromoSeq can find more genetic changes than current standard tests, and if it can be used in…

This study aims to develop special lab tests that can find tiny numbers of cancer cells left behind after treatment for acute myeloid leukemia (AML) or high-grade myelodysplastic syndrome (MDS). Researchers will follow 400 patients over time to see if these tests can predict whic…